Efficacy of Ultrasound-guided Injection of 5% Dextrose for Meralgia Paresthesia

6-month Efficacy of Ultrasound-guided Injection of 5% Dextrose for Meralgia Paresthesia

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06251882

Enrollment

Registered

2024-02-09

Start date

2022-01-01

Completion date

2024-01-30

Last updated

2024-02-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Meralgia Paresthetica

Keywords

ultrasound, meralgia paresthetica, D5W

Brief summary

Meralgia paresthetica (MP) is one of the most common peripheral entrapment neuropathies of the lower limbs. It is characterized by paresthesia, pain, tingling, numbness, hypersensitivity, or other abnormal skin sensations on the anterolateral aspect of the thigh. The condition results from compression of the lateral femoral cutaneous nerve (LFCN) along its course, often occurring as the nerve exits the pelvis.The injection of 5% dextrose (D5W) under ultrasound guidance is a novel treatment method for peripheral nerve entrapment. However, there is limited evidence about the efficacy of this method for patients with MP. The investigators found D5W was more safe and effective than corticosteroids for patients with MP. Thus, this study aimed to evaluate the 6-month efficacy of ultrasound-guided injection of D5W for MP patients.

Interventions

OTHERinjection

10ml D5W injection for MP patients

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* patients aged between 18 and 80 years; * those diagnosed with MP based on clinical and physical examination, with symptoms persisting for at least 3 months; * a high-resolution ultrasound revealing LFCN compression as it exited the pelvis.

Exclusion criteria

* MP resulting from trauma, surgery or occupying lesions affecting the LFCN; * pregnancy; * concurrent presence of rheumatic immune diseases, hypothyroidism, or diabetes mellitus; * a known history of allergy to lidocaine or corticosteroids; * L2/3 lumbar radiculopathy; * patients who had undergone local injection or surgery for MP within 3 months

Design outcomes

Primary

Measure	Time frame	Description
visual analogue scale(VAS)	baseline as well as 1month, 3 month, 6 months post-injection	VAS is one of the most common tool to assess pain severity for patients, ranging from 0(no pain) to 10(most possible pain).

Secondary

Measure	Time frame	Description
cross-sectional area(CSA) of the nerve	baseline as well as 1month, 3 month, 6 months post-injection	CSA could reflect the compression of the nerve, to some extent

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026